Hao-wei Teng

TPQ 11221, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 63 publications

Optimal timing of two-stage pulmonary metastasectomy for synchronous bilateral colorectal pulmonary metastases: A time-dependent survival analysis.

Optimal timing of two-stage pulmonary metastasectomy for synchronous bilateral colorectal pulmonary metastases: A time-dependent survival analysis.

Journal: Surgical oncology

Published: May 30, 2026

Circulating N6-methyladenosine RNA as a diagnostic and a stage-associated prognostic biomarker in colorectal cancer.

Circulating N6-methyladenosine RNA as a diagnostic and a stage-associated prognostic biomarker in colorectal cancer.

Journal: BMC cancer

Published: March 16, 2026

Optimizing third-line and beyond therapies for metastatic colorectal cancer in Taiwan: an evidence-based consensus.

Optimizing third-line and beyond therapies for metastatic colorectal cancer in Taiwan: an evidence-based consensus.

Journal: Therapeutic advances in medical oncology

Published: February 02, 2026

Early- vs. late-onset colon cancer: clinicopathological insights and survival outcomes in an East Asian cohort.

Early- vs. late-onset colon cancer: clinicopathological insights and survival outcomes in an East Asian cohort.

Journal: International journal of colorectal disease

Published: July 05, 2025

Colorectal cancer stem cells develop NK cell resistance via homotypic cell-in-cell structures suppressed by Stathmin1.

Colorectal cancer stem cells develop NK cell resistance via homotypic cell-in-cell structures suppressed by Stathmin1.

Journal: Theranostics

Published: January 13, 2025

Combining moderate dosage of Bevacizumab with TAS-102 provides longer progression-free time in refractory metastatic colorectal Cancer.

Combining moderate dosage of Bevacizumab with TAS-102 provides longer progression-free time in refractory metastatic colorectal Cancer.

Journal: International journal of colorectal disease

Published: November 18, 2024

Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.

Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 04, 2024

Expert consensus on the optimal management of BRAFV600E-mutant metastatic colorectal cancer in the Asia-Pacific region.

Expert consensus on the optimal management of BRAFV600E-mutant metastatic colorectal cancer in the Asia-Pacific region.

Journal: Asia-Pacific journal of clinical oncology

Published: May 15, 2024

The salvage lenvatinib-based regimen provides survival benefit in patients with refractory metastatic colorectal cancer.

The salvage lenvatinib-based regimen provides survival benefit in patients with refractory metastatic colorectal cancer.

Journal: American journal of cancer research

Published: February 18, 2024

The survival outcome differs between left-sided colon cancer and middle/low rectal cancer after colorectal hepatic metastasectomy.

The survival outcome differs between left-sided colon cancer and middle/low rectal cancer after colorectal hepatic metastasectomy.

Journal: Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract

Published: February 09, 2024

CT45A1-mediated MLC2 (MYL9) phosphorylation promotes natural killer cell resistance and outer cell fate in a cell-in-cell structure, potentiating the progression of microsatellite instability-high colorectal cancer.

CT45A1-mediated MLC2 (MYL9) phosphorylation promotes natural killer cell resistance and outer cell fate in a cell-in-cell structure, potentiating the progression of microsatellite instability-high colorectal cancer.

Journal: Molecular oncology

Published: November 17, 2023

Interferon Gamma Induces Higher Neutrophil Extracellular Traps Leading to Tumor-Killing Activity in Microsatellite Stable Colorectal Cancer.

Interferon Gamma Induces Higher Neutrophil Extracellular Traps Leading to Tumor-Killing Activity in Microsatellite Stable Colorectal Cancer.

Journal: Molecular cancer therapeutics

Published: November 14, 2023

Showing 1-12 of 63

Last Updated: 09/26/2026